caa a22 4500 397593848 CHVBK 20180308164946.0 cr unu---uuuuu 161202e199609 xx s 000 0 eng 10.1093/jac/38.3.485 doi (NATIONALLICENCE)oxford-10.1093/jac/38.3.485 In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system [Elektronische Daten] [Eryvaldo Sόcrates Tabosa Do Egito, Martine Appel, Hatem Fessi, Gillian Barrett, Francis Puisieux, Jean-Philippe Devissaguet] The in-vitro and in-vivo toxicity and activity of a new emulsion-based delivery system for amphotericin B (AmB-E) and of deoxycholate-amphotericin B (Fungizone) were studied. In vitro, Candida albicans and human red blood cells (RBCs) were treated with either product and dose-response curves for various cellular effects (changes in potassium cell content, haemoglobin leakage from RBCs and colony-forming ability of fungal cells) were obtained. AmB-E was less toxic than Fungizone against human RBCs and equally active against C. albicans cells. In-vivo studies showed that the LD50 of AmB-E and Fungizone in noninfected OF1 mice were 7.24 and 3.46 mg/kg, respectively. The therapeutic efficacy of AmB-E was assessed in murine candidiasis. Firstly, the efficacy of equal doses (0.8 mg/kg) of AmB-E and Fungizone was evaluated in infected mice. Both formulations increased the survival time compared to the control and were equally effective in reducing the cfu counts in the kidney. In the same model of infection, the maximum tolerated doses (MTD) of Fungizone and AmB-E were determined in order to study the efficacies of Fungizone and AmB-E at their respective MTD. AmB-E significantly increased the number of long-term survivors compared with Fungizone (MTD: 2 and 1 mg/kg, respectively). Thus, AmB-E was more effective than Fungizone for treatment of systemic mycoses at the MTD. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Do Egito Eryvaldo Sόcrates Tabosa Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Appel Martine Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Fessi Hatem Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Barrett Gillian Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Puisieux Francis Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Devissaguet Jean-Philippe Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/3(1996-09), 485-497 0305-7453 38:3<485 1996 38 jac https://doi.org/10.1093/jac/38.3.485 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.3.485 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Do Egito Eryvaldo Sόcrates Tabosa Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 700 1- Appel Martine Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 700 1- Fessi Hatem Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 700 1- Barrett Gillian Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 700 1- Puisieux Francis Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 700 1- Devissaguet Jean-Philippe Laboratoire de Pharmacie Galénique et Biopharmacie (URA CNRS 1218), Faculté de Pharmacie, Université Paris XI, 92296 Châtenay-Malabry Cedex, France aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/3(1996-09), 485-497 0305-7453 38:3<485 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford